Claudio Coracini
Chief Executive Officer chez BIOTOSCANA INVESTMENTS S.A.
Profil
Claudio Coracini is currently the Chief Executive Officer at Biotoscana Investments SA since 2019.
Prior to this, he worked as an Independent Director at Tempo Participações SA. Mr. Coracini completed his undergraduate and graduate degrees from Escola Superior de Propaganda e Marketing.
Postes actifs de Claudio Coracini
Sociétés | Poste | Début |
---|---|---|
BIOTOSCANA INVESTMENTS S.A. | Chief Executive Officer | 21/10/2019 |
Anciens postes connus de Claudio Coracini
Sociétés | Poste | Fin |
---|---|---|
TEMPO PARTICIPACOES SA | Director/Board Member | - |
Formation de Claudio Coracini
Escola Superior de Propaganda e Marketing | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Tempo Participações SA
Tempo Participações SA Managed Health CareHealth Services Tempo Participações SA engages in the provision of healthcare administration services. It operates through Home Care, and Specialized Assistance segments. The Home Care segment offers home assistance services to health plan operators, public self-management, private entities and private patients, including household hospitalization, and home care. The Specialized Assistance segment provides specialized assistance services, offering paid services based on a fixed monthly fee, including services for vehicles, roadside assistance and temporary replacement of vehicles; travel assistance, such as medical care, repatriation and assistance in case of baggage loss; domestic emergency services; and personal services such as funeral assistance and in accidents. The company was founded on January 1, 2006 and is headquartered in Barueri, Brazil. | Health Services |
Biotoscana Investments SA
Biotoscana Investments SA Pharmaceuticals: MajorHealth Technology Biotoscana Investments SA operates as a holding company, which engages in the development, manufacturing and commercialization of advanced medicine. Its operations include oncology, onco-hematology, severe infectious diseases, genetic and rare conditions as well as immunology and inflammation. The company was founded in August 16, 2011 and is headquartered in Montevideo, Uruguay. | Health Technology |